Millennium Management LLC Grows Stock Holdings in Prothena Co. PLC (NASDAQ:PRTA)

Millennium Management LLC raised its holdings in shares of Prothena Co. PLC (NASDAQ:PRTA) by 376.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,228,476 shares of the biotechnology company’s stock after acquiring an additional 970,503 shares during the quarter. Millennium Management LLC owned about 3.08% of Prothena worth $9,631,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of PRTA. California State Teachers Retirement System grew its position in shares of Prothena by 1.8% in the third quarter. California State Teachers Retirement System now owns 62,645 shares of the biotechnology company’s stock valued at $491,000 after purchasing an additional 1,126 shares in the last quarter. Swiss National Bank boosted its stake in Prothena by 2.2% in the 2nd quarter. Swiss National Bank now owns 74,200 shares of the biotechnology company’s stock worth $784,000 after purchasing an additional 1,600 shares during the period. Focused Wealth Management Inc boosted its stake in Prothena by 30.2% in the 3rd quarter. Focused Wealth Management Inc now owns 13,576 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 3,150 shares during the period. Bank of Montreal Can purchased a new position in Prothena during the 2nd quarter valued at about $36,000. Finally, UBS Asset Management Americas Inc. grew its holdings in Prothena by 12.8% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 30,815 shares of the biotechnology company’s stock valued at $326,000 after buying an additional 3,495 shares in the last quarter. Hedge funds and other institutional investors own 93.97% of the company’s stock.

A number of brokerages have recently issued reports on PRTA. Zacks Investment Research downgraded shares of Prothena from a “buy” rating to a “hold” rating and set a $11.00 price target on the stock. in a report on Wednesday, October 23rd. Evercore ISI raised shares of Prothena from an “in-line” rating to an “outperform” rating in a research note on Wednesday, November 27th. BidaskClub raised shares of Prothena from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, ValuEngine cut shares of Prothena from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $11.94.

Shares of NASDAQ PRTA opened at $12.85 on Friday. The stock’s 50-day simple moving average is $10.08 and its two-hundred day simple moving average is $9.24. Prothena Co. PLC has a twelve month low of $6.71 and a twelve month high of $14.77. The firm has a market capitalization of $512.68 million, a P/E ratio of -3.56 and a beta of 2.31. The company has a quick ratio of 12.88, a current ratio of 12.88 and a debt-to-equity ratio of 0.07.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.05. Prothena had a negative return on equity of 26.02% and a negative net margin of 10,450.00%. The firm had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.15 million. As a group, research analysts anticipate that Prothena Co. PLC will post -2 EPS for the current fiscal year.

Prothena Profile

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.

Recommended Story: How Investors Use a Balance Sheet

Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Co. PLC (NASDAQ:PRTA).

Institutional Ownership by Quarter for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.